Pages that link to "Q33339438"

The following pages link to Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. (Q33339438):

Displaying 34 items.

• Importance of domain closure for the autoactivation of ERK2. (Q30504224) (← links)
• Qingfei Xiaoyan Wan alleviates asthma through multi-target network regulation (Q30544207) (← links)
• Characterization of ERK docking domain inhibitors that induce apoptosis by targeting Rsk-1 and caspase-9. (Q33789572) (← links)
• Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells (Q33801399) (← links)
• Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing (Q33829484) (← links)
• Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases (Q33942964) (← links)
• BRAFV600E negatively regulates the AKT pathway in melanoma cell lines (Q34374407) (← links)
• Overexpression of eIF3e is correlated with colon tumor development and poor prognosis (Q34502089) (← links)
• Quantitative analysis of ERK2 interactions with substrate proteins: roles for kinase docking domains and activity in determining binding affinity (Q34509259) (← links)
• Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo (Q34581860) (← links)
• Mek1/2 gene dosage determines tissue response to oncogenic Ras signaling in the skin (Q34887145) (← links)
• Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging (Q34966603) (← links)
• Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health (Q35679353) (← links)
• Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032) (Q36057973) (← links)
• Small-molecule inhibitors of ERK-mediated immediate early gene expression and proliferation of melanoma cells expressing mutated BRaf (Q36276136) (← links)
• High mobility group-box 3 overexpression is associated with poor prognosis of resected gastric adenocarcinoma (Q36529224) (← links)
• Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases (Q36642420) (← links)
• Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response (Q36862768) (← links)
• Use of Inhibitors in the Study of MAP Kinases (Q37056518) (← links)
• Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy (Q37227994) (← links)
• Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics (Q37236103) (← links)
• Effect of API-1 and FR180204 on cell proliferation and apoptosis in human DLD-1 and LoVo colorectal cancer cells (Q37288375) (← links)
• Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy (Q37460333) (← links)
• A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors (Q37639582) (← links)
• NF‑κB inhibition is associated with OPN/MMP‑9 downregulation in cutaneous melanoma (Q37707767) (← links)
• The discovery of novel experimental therapies for inflammatory arthritis (Q37719255) (← links)
• A multipathway phosphoproteomic signaling network model of idiosyncratic drug- and inflammatory cytokine-induced toxicity in human hepatocytes (Q37721819) (← links)
• Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer (Q38238743) (← links)
• Challenges in the delivery of therapies to melanoma brain metastases (Q39331752) (← links)
• Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies (Q39383689) (← links)
• Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate). (Q39514463) (← links)
• Homology modeling and atomic level binding study of Leishmania MAPK with inhibitors (Q39958465) (← links)
• Cytokine-associated drug toxicity in human hepatocytes is associated with signaling network dysregulation (Q42423679) (← links)
• Cardiac Hormones Target the Ras-MEK 1/2-ERK 1/2 Kinase Cancer Signaling Pathways (Q42448356) (← links)